Integral Liquid Biopsy
The innovative 4D Lifetest™ Technology
Current efforts to develop early detection of cancer into the clinic focus mainly on PCR and liquid biopsies. These methods intend to use cancer patient’s blood to detect hints of specific tumor cells or tumor related DNA/RNA. Because these methods will create very specific information on the kind and the status of the tumor, either the reliability or the efficiency of this methods today are still limited by the variety of tumor cells, the limited sensitivity, the lack of standardization and the related high costs.
4D Lifetec AG developed the 4D LifetestTM – an innovative, standardized, cost effective ultra-precise integral liquid biopsy assay. Integral Liquid Biopsy (ILB) is a progression of current liquid biopsy assays, measuring the level of DNA repair in white and red blood cells which reliably correlates with primary tumor affection at an early stage. It is a prescreening diagnostic assay creating general information on tumor affection at all stages prior to further investigation via cancer-specific assays. 4D Lifetec has successfully translated the reduced level of information (yes/no) of the assay into an innovative and effective setup combining reduced costs with ultra-precision and mass screening potential. 4D LifetestTM has the potential to measure 10’000 data points per day at a cost level of approximately 1$ per point.
4D LifetestTM has already proven its ability to detect early-stage cancer in general due to DNA repair suppression in patients affected by any kind of cancer. Clinical trials have shown its potential as a simple, single, empirical assay to select any early-stage cancer (Early Cancer Diagnostics). Further clinical trials are planned for the future.
Early Cancer Diagnostics
Proven Clinical Evidence of
Clinical trials have reported the potential of integral liquid biopsy to differentiate between control, pre- and cancer patients (Anderson et al., The FASEB Journal Vol. 28, No. 10, pp: 4563-4570, October, 2014) for different cancer types. However, these promising clinical results were not scalable for standard diagnostics because of a lack of standardization of the available test equipment. With the 4D LifetestTM we innovated an adequate algorithm controlled and standardized system to reach reproducibility and precision required to make integral liquid biopsy a reliable diagnostic assay. With significant funding of the Swiss Commission for Technology and Innovation (CTI), the Swiss Federal Institute for Materials Science and Technology Research (EMPA) has demonstrated the breakthrough potential of 4D LifetestTM being an ultra-precise, cost-effective and high throughput GLP compliant automated integral liquid biopsy test system.
First clinical trials using the 4D LifetestTM on fresh human biopsies at International Cancer Centers have clearly resulted in reproducible and reliable identification of affected patients. Furthermore, the preliminary data suggests the potential of our method to differentiate between different levels of aggressiveness of the measured tumors.
"We have been amazed by the unprecedented reproducibility and precision of the 4D LifetestTM. It gives you results you can trust. Importantly, we can now compare DNA damage measurements from different runs with peace of mind. Moreover, it is very easy to use and shortens working time in the laboratory. “
Dr. Jean-Sébastien Hoffmann, INSERM, Cancer Research Center of Toulouse
What if... the vision of 4D Lifetec to open the door to effective Cancer Prediction
It is our vision at 4D Lifetec not only to realize effective Early Cancer Diagnostics in the near future but go a step further. We would like to open the door to establish cancer prediction. We have established a standardized test protocol as part of the 4D LifetestTM to obtain statistically relevant data outcome of diagnostic population screenings. The cost effectiveness of the assay will allow us the continuous mass application on 100% populations over time (Human Biomonitoring). The fact that for the first time an affordable human biomonitoring seems accessible opens the door to generate not only standardized clinical patient statistics but also clinical population statistics. Therefore 4d LifetestTM has the outstanding potential to create clinical context to verifying social data generated from populations (Social Datamonitoring). Effectively this would help us specifying risk factors of cancer and would open the door for predictive cancer analytics for individuals being at risk to be affected.